Myriad Genetics Inc

Latest Results (11.10.2025):

Myriad Genetics Inc reported its financial results for the second quarter of 2025, showcasing modest revenue growth and improvements in gross margins, while navigating challenges related to market capitalization that resulted in a significant net loss. The company has also raised its 2025 revenue guidance in light of positive business momentum and secured additional financial flexibility through a new credit facility.

Revenue Growth

The company's second quarter 2025 revenue reached $213.1 million, representing a 1% year-over-year increase. When excluding headwinds of $9.5 million, revenue growth stood at 5% compared to the same period last year.

Oncology Testing Expansion

Hereditary cancer testing revenue in the second quarter of 2025 grew by 9% year-over-year, with a 10% increase in testing volume. Notably, MyRisk with RiskScore testing volume in oncology saw a 14% year-over-year growth.

Improved Gross Margins

Myriad Genetics achieved a gross margin of 71.2% in the second quarter of 2025, an increase of 160 basis points compared to the previous year, driven by an optimized product mix, enhanced revenue per test, and greater laboratory efficiencies.

Financial Loss and Impairment Charges

The company reported a GAAP net loss of $330.5 million, or $(3.57) per share, in the second quarter of 2025. This loss includes non-cash impairment charges of $316.7 million, primarily due to a decline in the company's market capitalization year-to-date. Adjusted earnings per share were $0.05.

New Credit Facility

On July 31, 2025, Myriad Genetics entered into a new $200 million credit facility to enhance financial flexibility and support the company’s growth strategy.

Raised Revenue Guidance

The company has raised its 2025 revenue guidance to a range of $818 - $828 million, up from the previous projection of $807 - $823 million, while maintaining the adjusted earnings per share forecast of $(0.02) - $0.02.